TN2010000107A1 - Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3 - Google Patents

Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3

Info

Publication number
TN2010000107A1
TN2010000107A1 TNP2010000107A TN2010000107A TN2010000107A1 TN 2010000107 A1 TN2010000107 A1 TN 2010000107A1 TN P2010000107 A TNP2010000107 A TN P2010000107A TN 2010000107 A TN2010000107 A TN 2010000107A TN 2010000107 A1 TN2010000107 A1 TN 2010000107A1
Authority
TN
Tunisia
Prior art keywords
azacyclylisoquinolinone
receptor antagonists
histamine receptor
isoindolinone derivatives
isoindolinone
Prior art date
Application number
TNP2010000107A
Other languages
English (en)
Inventor
Dahui Zhou
Jonathan Laird Gross
Albert Jean Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of TN2010000107A1 publication Critical patent/TN2010000107A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (I) et son utilisation pour le traitement d'un trouble du système nerveux central en rapport avec ou influencé par le récepteur de l'histamine-3.
TNP2010000107A 2007-09-12 2010-03-11 Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3 TN2010000107A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99355407P 2007-09-12 2007-09-12
PCT/US2008/075942 WO2009036117A1 (fr) 2007-09-12 2008-09-11 Dérivés d'azacyclylisoquinolinone et d'isoindolinone convenant comme antagonistes de l'histamine-3

Publications (1)

Publication Number Publication Date
TN2010000107A1 true TN2010000107A1 (fr) 2011-09-26

Family

ID=40261508

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000107A TN2010000107A1 (fr) 2007-09-12 2010-03-11 Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3

Country Status (23)

Country Link
US (1) US20090069370A1 (fr)
EP (1) EP2200998A1 (fr)
JP (1) JP2010539178A (fr)
KR (1) KR20100054852A (fr)
CN (1) CN101842366A (fr)
AP (1) AP2010005199A0 (fr)
AU (1) AU2008298983A1 (fr)
BR (1) BRPI0816806A2 (fr)
CA (1) CA2699383A1 (fr)
CL (1) CL2008002708A1 (fr)
CO (1) CO6300951A2 (fr)
CR (1) CR11309A (fr)
DO (1) DOP2010000078A (fr)
EA (1) EA201000319A1 (fr)
EC (1) ECSP10010032A (fr)
MA (1) MA31700B1 (fr)
MX (1) MX2010002899A (fr)
NI (1) NI201000035A (fr)
PA (1) PA8795601A1 (fr)
PE (1) PE20090679A1 (fr)
TN (1) TN2010000107A1 (fr)
TW (1) TW200918062A (fr)
WO (1) WO2009036117A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
JP2011213700A (ja) * 2010-04-02 2011-10-27 Nishizaki Soyaku Kenkyusho:Kk 認知症改善用組成物
AR081908A1 (es) 2010-05-11 2012-10-31 Sanofi Aventis N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
EP2569303A1 (fr) 2010-05-11 2013-03-20 Sanofi Dérivés n-alkyl et n-acyl tétrahydro-isoquinoline substitués, procédé de préparation et application thérapeutiques associés
EP2569297A1 (fr) 2010-05-11 2013-03-20 Sanofi Dérivés de n-hétérocycloalkyl-bipyrrolidinylphénylamide substitués, préparation et utilisation thérapeutique de ceux-ci
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
EP2717933B1 (fr) 2011-06-13 2019-05-01 Dentsply IH AB Article revêtu de collagène
EP2535062A1 (fr) 2011-06-13 2012-12-19 Dentsply IH AB Article revêtu de collagène
AR088989A1 (es) * 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
PT3063139T (pt) 2013-10-29 2019-02-22 Takeda Pharmaceuticals Co Composto heterocíclico
CN112209876B (zh) * 2020-10-15 2022-08-26 华侨大学 一种3-三氟甲基异喹啉酮衍生物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
AU4319797A (en) * 1996-09-25 1998-04-17 Yamanouchi Pharmaceutical Co., Ltd. 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives or medicinal compositions thereof
WO1998048800A1 (fr) * 1997-05-01 1998-11-05 Eli Lilly And Company Agents antithrombotiques
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
KR101748290B1 (ko) * 2004-05-14 2017-06-16 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 방법
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7482468B2 (en) * 2005-01-21 2009-01-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
EP1877401A2 (fr) * 2005-04-15 2008-01-16 Elan Pharmaceuticals Inc. Nouveaux composes s'utilisant dans l'antagonisme du recepteur de bradykinine b1
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators

Also Published As

Publication number Publication date
MA31700B1 (fr) 2010-09-01
CN101842366A (zh) 2010-09-22
CR11309A (es) 2010-04-07
AP2010005199A0 (en) 2010-04-30
ECSP10010032A (es) 2010-08-31
JP2010539178A (ja) 2010-12-16
CO6300951A2 (es) 2011-07-21
WO2009036117A1 (fr) 2009-03-19
PA8795601A1 (es) 2009-05-15
AU2008298983A1 (en) 2009-03-19
CA2699383A1 (fr) 2009-03-19
MX2010002899A (es) 2010-04-09
EP2200998A1 (fr) 2010-06-30
DOP2010000078A (es) 2010-04-15
CL2008002708A1 (es) 2008-10-10
PE20090679A1 (es) 2009-05-28
BRPI0816806A2 (pt) 2015-03-10
TW200918062A (en) 2009-05-01
KR20100054852A (ko) 2010-05-25
EA201000319A1 (ru) 2010-10-29
US20090069370A1 (en) 2009-03-12
NI201000035A (es) 2010-07-15

Similar Documents

Publication Publication Date Title
TN2010000107A1 (fr) Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3
TN2010000105A1 (fr) Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31910B1 (fr) Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepine
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA34509B1 (fr) Composé hétérocyclique et son utilisation
WO2008056259A3 (fr) Dérivés d'oxazole utilisés en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
MY155212A (en) Quaternary ammonium salt compounds
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA32751B1 (fr) Antagoniste sélectif du récepteur opioïde kappa
MA33492B1 (fr) Inhibiteurs de bace
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
UA100695C2 (ru) 2,3-дигидробензо[1,4] диоксин-2-илметиловые производные как альфа2с антагонисты для применения в лечении заболеваний периферической и центральной нервной системы
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten
GB0508717D0 (en) Chemical compounds
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
MX2009012734A (es) Derivados de azaciclilbenzamida como antagonistas de histamina-3.
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.